Accolade, Inc.

NasdaqGS:ACCD Stock Report

Mkt Cap: US$990.6m

We’ve recently updated our valuation analysis.

Accolade Valuation

Is ACCD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACCD?

Other financial metrics that can be useful for relative valuation.

ACCD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ACCD's PS Ratio compare to its peers?

The above table shows the PS ratio for ACCD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2x
CCRN Cross Country Healthcare
0.3x-9.9%US$839.9m
FLGT Fulgent Genetics
1.5x-21.7%US$918.6m
DCGO DocGo
2x13.1%US$883.6m
CSTL Castle Biosciences
4.4x18.4%US$598.2m
ACCD Accolade
2.8x15.5%US$990.6m

Price to Earnings Ratio vs Industry

How does ACCD's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
 n/an/an/a
No more companies

Price to Sales Ratio vs Fair Ratio

What is ACCD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACCD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: ACCD is expensive based on its Price-To-Sales Ratio (2.8x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Share Price vs Fair Value

What is the Fair Price of ACCD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACCD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$13.61
US$13.61
-0.02%
14.2%US$17.00US$10.00n/a14
Mar ’24US$12.39
US$13.19
+6.5%
12.0%US$15.00US$10.00n/a13
Feb ’24US$11.84
US$13.04
+10.1%
12.3%US$15.00US$10.00n/a13
Jan ’24US$7.79
US$13.93
+78.8%
14.2%US$17.00US$10.00n/a14
Dec ’23US$8.97
US$13.93
+55.3%
14.2%US$17.00US$10.00n/a14
Nov ’23US$10.91
US$13.93
+27.7%
14.2%US$17.00US$10.00n/a14
Oct ’23US$11.42
US$12.14
+6.3%
20.1%US$16.00US$8.00n/a14
Sep ’23US$10.45
US$11.58
+10.8%
20.9%US$16.00US$8.00n/a13
Aug ’23US$9.53
US$11.06
+16.0%
18.3%US$15.00US$8.00n/a13
Jul ’23US$9.53
US$10.69
+12.2%
19.9%US$15.00US$8.00n/a13
Jun ’23US$5.83
US$13.00
+123.0%
54.6%US$35.00US$6.00n/a13
May ’23US$5.56
US$17.23
+209.9%
56.4%US$35.00US$8.00n/a13
Apr ’23US$18.88
US$35.31
+87.0%
17.2%US$52.00US$30.00n/a13
Mar ’23US$16.89
US$36.23
+114.5%
17.2%US$52.00US$30.00US$12.3913
Feb ’23US$19.75
US$38.25
+93.7%
21.2%US$55.00US$30.00US$11.8412
Jan ’23US$26.36
US$49.73
+88.6%
21.2%US$62.00US$31.00US$7.7911
Dec ’22US$24.34
US$54.42
+123.6%
14.9%US$62.00US$33.00US$8.9712
Nov ’22US$40.34
US$56.36
+39.7%
9.0%US$62.00US$45.00US$10.9111
Oct ’22US$42.69
US$61.82
+44.8%
6.3%US$68.00US$54.00US$11.4211
Sep ’22US$48.23
US$63.00
+30.6%
6.5%US$70.00US$58.00US$10.4510
Aug ’22US$46.81
US$63.00
+34.6%
6.5%US$70.00US$58.00US$9.5310
Jul ’22US$54.36
US$58.40
+7.4%
4.0%US$60.00US$54.00US$9.535
Jun ’22US$51.05
US$58.42
+14.4%
4.1%US$62.00US$54.00US$5.8312
May ’22US$50.15
US$58.73
+17.1%
5.3%US$65.00US$54.00US$5.5611
Apr ’22US$46.86
US$58.56
+25.0%
5.8%US$65.00US$54.00US$18.889
Mar ’22US$47.08
US$58.56
+24.4%
5.5%US$65.00US$54.00US$16.899

Discover undervalued companies